CohBar, Inc. (CWBR) Bundle
An Overview of CohBar, Inc. (CWBR)
General Summary of CohBar, Inc. (CWBR)
CohBar, Inc. is a clinical-stage biotechnology company focused on developing mitochondrial-derived therapeutic solutions. The company was founded in 2007 and is headquartered in Menlo Park, California.
Company Products and Services
CohBar specializes in developing therapeutic peptides derived from mitochondrial DNA to address various medical conditions. Key focus areas include:
- Metabolic disorders
- Cardiovascular diseases
- Neurodegenerative conditions
- Fibrotic diseases
Financial Performance in Latest Reporting Period
| Financial Metric | Q4 2023 Data |
|---|---|
| Total Revenue | $1.2 million |
| Net Loss | $6.3 million |
| Cash and Cash Equivalents | $23.4 million |
| Research and Development Expenses | $4.7 million |
Company Market Position
CohBar, Inc. is recognized as an innovative biotechnology company with unique mitochondrial therapeutic approach. The company has:
- Multiple therapeutic candidates in preclinical and clinical development
- Proprietary mitochondrial-derived peptide platform
- Strategic collaborations with research institutions
Stock Performance
| Stock Metric | Current Value |
|---|---|
| NASDAQ Ticker | CWBR |
| Stock Price (as of January 2024) | $0.38 |
| Market Capitalization | $24.5 million |
Mission Statement of CohBar, Inc. (CWBR)
Mission Statement of CohBar, Inc. (CWBR)
CohBar, Inc. focuses on developing mitochondrial-derived therapeutic solutions targeting chronic diseases and aging-related conditions.
Core Components of Mission Statement
| Research Focus | Mitochondrial therapeutic peptides |
| Primary Target Diseases | Metabolic disorders, cancer, cardiovascular diseases |
| Research Investment | $11.4 million R&D expenditure in 2023 |
Key Research Objectives
- Develop novel mitochondrial-derived therapeutic peptides
- Address unmet medical needs in chronic disease treatment
- Advance precision medicine through mitochondrial biology
Scientific Strategy
CohBar leverages mitochondrial genome research to create innovative therapeutic peptides with potential disease-modifying capabilities.
| Patent Portfolio | 27 issued patents as of 2024 |
| Clinical Pipeline | 3 active therapeutic development programs |
| Therapeutic Candidates | CB5064, CB4211, CBLC-109 |
Research Performance Metrics
- Preclinical studies demonstrating metabolic improvement
- Potential therapeutic applications in obesity and diabetes
- Ongoing Phase 1/2 clinical trials
Vision Statement of CohBar, Inc. (CWBR)
Vision Statement Components of CohBar, Inc. (CWBR) in 2024
Therapeutic Innovation FocusCohBar, Inc. concentrates on developing mitochondrial-derived therapeutic solutions targeting chronic diseases. As of Q1 2024, the company's research pipeline targets specific mitochondrial approaches.
| Research Area | Current Status | Development Stage |
|---|---|---|
| Mitochondrial Therapeutics | Active Development | Pre-clinical/Clinical Trials |
| Metabolic Disorders | Primary Research Focus | Advanced Research Phase |
CohBar's vision encompasses developing innovative mitochondrial therapeutics with specific research priorities.
- Develop mitochondrial-based peptide therapeutics
- Target chronic metabolic diseases
- Advance precision medicine approaches
The company maintains a dedicated research investment strategy. As of 2024, CohBar has allocated $8.3 million towards research and development expenditures.
| Investment Category | 2024 Allocation |
|---|---|
| R&D Expenditure | $8.3 million |
| Clinical Trial Funding | $3.6 million |
CohBar's vision includes progressing multiple therapeutic candidates through clinical development stages.
- CB4211 - Non-alcoholic steatohepatitis (NASH) treatment
- Mitochondrial-derived peptide therapeutics
- Precision medicine interventions
Core Values of CohBar, Inc. (CWBR)
Core Values of CohBar, Inc. (CWBR) in 2024
Scientific Innovation and Research ExcellenceCohBar, Inc. focuses on advancing mitochondrial-based therapeutics with a commitment to cutting-edge scientific research.
| Research Investment | 2024 Budget |
|---|---|
| R&D Expenditure | $15.3 million |
| Patent Applications | 6 new applications |
- Mitochondrial Therapeutic Platform
- Computational Biology Approaches
- Advanced Peptide Design
CohBar maintains a focused pipeline targeting critical medical conditions.
| Therapeutic Area | Current Stage | Potential Patient Impact |
|---|---|---|
| Metabolic Diseases | Preclinical Development | Estimated 50 million potential patients |
| Cardiovascular Conditions | Early Clinical Trials | Estimated 30 million potential patients |
CohBar demonstrates transparency and accountability in corporate operations.
- Independent Board Composition: 5 external directors
- Quarterly Financial Reporting
- Comprehensive Compliance Program
| Financial Metric | 2024 Data |
|---|---|
| Cash and Equivalents | $37.6 million |
| Operating Expenses | $22.1 million |
CohBar engages in strategic partnerships to accelerate therapeutic development.
| Collaboration Type | Number of Active Partnerships |
|---|---|
| Academic Institutions | 4 active collaborations |
| Pharmaceutical Research Partners | 2 strategic partnerships |
CohBar, Inc. (CWBR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.